Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_assertion type Assertion NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_head.
- NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_assertion wasGeneratedBy ECO_0000203 NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_provenance.
- NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_assertion wasDerivedFrom befree-20150227 NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_provenance.
- NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_assertion SIO_000772 25511139 NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_provenance.
- NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_assertion evidence source_evidence_literature NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_provenance.
- NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_assertion description "[Loss of CD52 expression in RS most likely predicts resistance to alemtuzumab therapy, which is frequently used in CLL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP308472.RA8cEDJfMd-tFihCsay5F4FZKrQCg7QmEFLVKgNARKTss130_provenance.